{"id":"vdphl01","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-15%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting H3 HDAC, VDPHL01 aims to modulate gene expression and potentially treat various diseases. This mechanism is being explored in phase 3 clinical trials, but more research is needed to fully understand its effects.","oneSentence":"VDPHL01 is a small molecule that targets the H3 histone deacetylase (HDAC) enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:47.025Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT06972264","phase":"PHASE3","title":"Safety and Efficacy of VDPHL01 in Males With AGA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Veradermics, Inc.","startDate":"2025-03-11","conditions":"Androgenetic Alopecia, AGA, Male Pattern Baldness","enrollment":480},{"nctId":"NCT07146022","phase":"PHASE3","title":"Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)","status":"RECRUITING","sponsor":"Veradermics, Inc.","startDate":"2025-07-25","conditions":"Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA","enrollment":552},{"nctId":"NCT06724614","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of VDPHL01 in Males With AGA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Veradermics, Inc.","startDate":"2024-11-06","conditions":"Androgenetic Alopecia, AGA, Male Pattern Baldness","enrollment":480},{"nctId":"NCT06527365","phase":"PHASE2","title":"Safety and Efficacy of VDPHL01 in Males and Females With AGA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Veradermics, Inc.","startDate":"2024-07-08","conditions":"Androgenetic Alopecia, AGA, Male Pattern Baldness","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VDPHL01","genericName":"VDPHL01","companyName":"Veradermics, Inc.","companyId":"veradermics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VDPHL01 is a small molecule that targets the H3 histone deacetylase (HDAC) enzyme. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}